µ²ºc¦¡ |
|
Ibandronic acid [1-hydroxy-3-(methyl-pentyl-amino)-1-phosphono-propyl]phosphonic acid
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Ibandronate °©Àf²Õ´ªº§@¥Î«Y°ò©ó¹ï²B®ð°òÁC¦Ç¥Û(hydroxyapatite)ªº¿Ë©M¤O¡A²B®ñ°òÁC¦Ç¥Û¬O°©ÀfÄqª«½è°ò½èªº¤@³¡¤À¡CIbandronate ¥i§í¨î»k°©²ÓMªº¬¡©Ê¡A¨Ã°§C°©Àf·»»k§@ ¥Î¤Î°©¸m´«§@¥Î(bone turnover)¡C¹ï°±¸g«áªº°ü¤k¦Ó¨¥¡A¥»«~¥i°§Cì¤w¤É°ªªº°©¸m´«²v¡A±q¦Ó´£°ª°©½è§t¶qªº¥§¡²bÈ¡C
|
¾AÀ³¯g |
|
¥Î©óªvÀø°±¸g«á°ü¤k¤§°©½è²¨ÃP¯g(BMD TSCORE < -2.5 SD)¡A¥H´î¤Ö¯á´Õ°©°©§é¡C
|
¥Îªk¥Î¶q |
|
Ibandronate Sodium ª`®g¾¯¥Î©óªvÀø°±¸g«á°©½è²¨ÃP¯g®Éªº«Øij¾¯¶q¬°¨C3 Ó¤ë¤@¦¸¡A¥H15 ¦Ü30 ¬íªº®É¶¡ÀR¯ßª`®g3 ²@§J¡C
|
ÃİʤO¾Ç |
|
¤À§G ÀR¯ßª`®g§ë¤©2²@§J¦Ü6²@§Jªº¾¯¶q¤§«á¡A¦å²Mibandronate¿@«×®É¶¡¦±½u¤U±¿n·|ÀH¾¯¶q¦¨¤ñ¨Ò¤É°ª¡C §ëÃÄ«á¡Aibandronate·|§Ö³t¦a©M°©Àfµ²¦X©Î¬O±Æ¤J§¿¤¤¡C¦b¤HÅ餤¡A¨äÀÀ¦ü³Ì²×¤À§GÅé¿n¦Ü¤Ö¬°90¤½¤É¡A¦Û´`Àô¤¤¶i¤J°©Àfªº¾¯¶q¬ù¬°´`Àô¾¯¶qªº40%¦Ü50%¡Cibandronate¦b20¦Ü2000 ng/mL (±µªñÀR¯ßª`®g«áªº³Ì°ª¦å²Mibandronate¿@«×½d³ò)¤§¿@«×½d³ò¤ºªºÅé¥~¤HÃþ¦å²M³J¥Õµ²¦X²v¬ù¬°86%¡C ¥NÁ ¥Ø«e¨ÃµL¥ô¦óÃÒ¾ÚÅã¥Üibandronate¦b¤HÅ餺·|³Q¥NÁ¡CÅé¥~¸ÕÅçÅã¥Ü¡Aibandronate¨Ã¤£·|§í¨î¤HÃþªºP450 1A2¡B2A6¡B2C9¡B2C19¡B2D6¡B2E1¤Î3A4¦P¥\»Ã¯À¡C ±Æ°£ Ibandronate¥¼¸g°©Àf§l¦¬¦Ó¦Û´`Àô¤¤²¾¥Xªº³¡¥÷·|¥H¥¼§ïÅܪº§Î¦¡¸g¥ÑµÇŦ±Æ°£(¬ù¬°ÀR¯ßª`®g¾¯¶qªº50%¦Ü60%)¡C Ibandronateªº¦å¤¤±Æ°£¬O¤@Ó¦h¬Ûªº¹Lµ{¡CµÇŦ²M°£¤Î¤À§G¶i¤J°©Àfªº§@¥Î·|«P¨Ï¨ä¦å¤¤¿@«×§Ö³t¤U°¡AR¯ßª`®g©Î¤fªA§ë¤©«á¤À§O·|©ó3¤Î8¤p®É¤º°¦ÜCmaxªº10%¡C±µµÛ¬O¤@Ó¸û¬°½wºCªº²M°£¶¥¬q¡Aibandronate·|±q°©Àf¦A¤À§G¨ì¦å²G¤¤¡CIbandronateªºÆ[¹î©Ò¨£ÀÀ¦ü³Ì²×¥b°I´Á³q±`nµø¬ã¨s©Ò±Ä¥Îªº¾¯¶q¥H¤Î¤ÀªR¤èªkªº±Ó·P«×¦Ó©w¡C¥H2¤p®Éªº®É¶¡ÀR¯ß¿éª`2²@§J¤Î4²@§Jªºibandronate¤§«á¡A¨äÆ[¹î©Ò¨£³Ì²×¥b°I´Áªº½d³ò¤À§O¬°4.6¦Ü15.3¤p®É»P5¦Ü25.5¤p®É¡C ÀR¯ßª`®g«á¡AibandronateªºÁ`²M°£²v«Ü§C¡A¥§¡È¬°84¦Ü160²@¤É/¤ÀÄÁ¡CµÇŦ²M°£²v(°·±d°±¸g«á°ü¤k¬ù¬°60²@¤É/¤ÀÄÁ)¦ûÁ`²M°£²vªº50%¦Ü60%¡A¨Ã¥B©M¦Ù»ÄÓþ²M°£²v¨ãÃöÁp©Ê¡CÀÀ¦üÁ`²M°£²v»PµÇŦ²M°£²v¶¡ªº®t²§©Î³\¥i¤ÏÀ³¥X¦¹ÃĪ«·|³Q°©Àf§l¦¬¡C ¯S®í±Ú¸s µÇ¥\¯à¤£¥þ Ibandronate¦b¦UºØ¤£¦Pµ{«×¤§µÇ¥\¯à¤£¥þ±wªÌÅ餺ªºµÇŦ²M°£²v©M¦Ù»ÄÓþ²M°£²v(CLcr)§e½u©ÊÃö«Y¡C ÀR¯ßª`®g§ë¤©¤@¾¯0.5²@§Jªºibandronate¤§«á¡ACLcr¬°40¦Ü70²@¤É/¤ÀÄÁ¤§±wªÌªºÃnÅS¶q(AUC„V)n¤ñCLcr>90²@¤É/¤ÀÄÁ¤§¨ü¸ÕªÌ¤¤©Ò¨£ªºÃnÅS¶q°ª¥X55%¡C©M°·±d¨ü¸ÕªÌ¬Û¤ñ¸û¡ACLcr<30²@¤É/¤ÀÄÁ¤§±wªÌªºÃnÅS¶q·|¤É°ª2¿¥H¤W¡C
|
°Æ§@¥Î |
|
§C¦å¶t¡B°ª¦å¯×¡B¥|ªÏ¯kµh¡BIµh¡B®ø¤Æ¤£¨}¡BÃE°©Ãa¦º¡C
|
¥æ¤¬§@¥Î |
|
Ibandronate ¨Ã¤£·|¶i¦æ¨xŦ¥NÁ¡A¤]¤£·|§í¨î¨xŦªº²ÓM¦â¯ÀP450 ¨t²Î¡CIbandronate«Y¸g¥ÑµÇŦ±Æªn§@¥Î±Æ¥XÅé¥~¡C¤@¶µ¤j¹«¬ã¨sÅã¥Ü¡AIbandronate ªº¤Àªc³~®|¦ü¥G¨Ã¤£¥]¬A·|¯A¤Î±Æªn¨ä¥LÃĪ«ªº»Ä©Ê©ÎÆP©Ê¶Ç¿é¨t²Î¡C Melphalan / Perdnisolone ¤@¶µ°w¹ï¦hµo°©Åè½F±wªÌ©Ò¶i¦æªºÃĪ«°Ê¤O¾Ç¥æ¤¬§@¥Î¬ã¨sÅã¥Ü¡AÀR¯ßª`®g§ë¤©ªºmelphalan(10 ²@§J/¥¤è¤½¤Ø)¤Î¤fªA§ë¤©Prednisolone(10 ²@§J/¥¤è¤½¤Ø)³£¤£·|»P¦P®ÉÀR¯ßª`®g§ë¤©ªº6 ²@§JIbandronate ²£¥Í¥æ¤¬§@¥Î¡CIbandronate ¤£·|»PMelphalan ©ÎPerdnisolone ²£¥Í¥æ¤¬§@¥Î¡C Tamoxifen ¤@¶µ°w¹ï°·±d°±¸g«á°ü¤k©Ò¶i¦æªºÃĪ«°Ê¤O¾Ç¥æ¤¬§@¥Î¬ã¨sÅã¥Ü¡A¤fªA§ë¤©ªº30 ²@§Jtamoxifen »PÀR¯ßª`®g§ë¤©ªº2 ²@§JIbandronate ¤§¶¡¨ÃµL¥ô¦ó¥æ¤¬§@¥Î¡C
|
¸T§Ò |
|
1. ¤wª¾¹ïIbandronate Sodium ª`®g¾¯©Î¨ä¥ô¦ó½á§Î¾¯¹L±ÓªÌ¡C 2. ¥¼¸gÁBªvªº§C¦å¶t¯g¡C
|
µ¹¥I³W©w |
|
(1)¥Î©ó°±¸g«á°ü¤k¡]alendronate¡Bzoledronate¡Bdenosumab¤Îrisedronate¥ç¥i¨Ï¥Î©ó¨k©Ê¡^¦]°©½è²¨ÃP¯g¡]¶·¸gDXA ÀË´úBMD¤§T score¡Ø -2.5SD¡^¤Þ°_¯á´Õ©ÎÆb³¡°©§é¡A©Î¦]°©½è²¨¤Ö¯g(osteopenia)(¸gDXAÀË´úBMD¤§-2.5SD (2)ªvÀø®É¡A¤@¦¸¥Î¤@¶µÃĪ«¡A¤£±o¨Ö¥Î¨ä¥L°©½è²¨ÃP¯gªvÀøÃĪ«¡C (3)¨Ï¥ÎÂùÁC»ÄÆQÃþÃĪ«¡A¶·¥ýÀË´ú¯f±w¤§¦å²Mcreatinine¿@«×¡A²Å¦X¸Ó¶µÃĪ«¥é³æ¤§«Øij³W©w¡C
|
ª`·N¨Æ¶µ |
|
Ibandronate Sodium ª`®g¾¯¤£¥i¥Î©ó¨Ö¦³ÄY«µÇ¥\¯à·l®`ªº±wªÌ¡A (¥ç§Y¦å²M¦Ù»ÄÓþ>200£gmol/L[2.3mg/dL])©Î¦Ù»ÄÓþ²M°£²v[ÀË´úȩΦôºâÈ]<30 ²@¤É/¤ÀÄÁªº±wªÌ)¡C
|
ĵ»y |
|
1. ©M¨ä¥¦ÀR¯ßª`®g¥ÎÂùÁC»ÄÆQÃþÃĪ«¤@¼Ë¡AIbandronate Sodium ª`®g¾¯¥i¯à·|¾ÉP¼È®É©Êªº¦å¶tÈ°§C¡C 2. Ibandronate Sodium ª`®g¾¯¶È¥iÀR¯ßª`®g§ë¤©¡C¨Ï¥Î®É°È¥²¤p¤ß¡A¤£n±NIbandronate Sodium ª`®g¾¯ª`¤J°Ê¯ß©Îª`¤JÀR¯ß®Ç°¼¡A¦]¬°³o¼Ë¥i¯à·|¾ÉP²Õ´·l®`¡C
|
¹L¶q³B²z |
|
¦bIbandronate Sodium ª`®g¾¯ªº¤W¥««e¬ã¨s¤¤¡A¨ÃµL¥ô¦ó¥ÎÃĹL¶qªº¯f¨Ò³ø§i¡CÀR¯ßª`®g¹L¶q¥i¯à·|¾ÉP§C¦å¶t¡B§CÁC»Ä¦å¯g¤Î§C¦åÁâ¡C¦pªG¥X²{¨ãÁ{§ÉÃöÁp©Êªº¶t¡BÁC¡B¤ÎÁâ¦å²M¿@«×°§Cªº²{¶H¡AÀ³¤À§O¥HÀR¯ßª`®g¸²µå»Ä¶t¡BÁC»Ä¹[©ÎÁC»Ä¶u¡B¤Î²¸»ÄÁ⪺¤è¦¡ÁBªv¡C³zªR¥i¯à¨ÃµL§U¯q¡A°£«D¬O¦b§ëÃĹL¶q«áªº2 ¤p®É¤º¶i¦æ¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
½Ð¦s©ñ©ó30¢J¥H¤U¡CÁקK°ª·Å¤Î·Ã®ð¡C
|